Upstream Bio
Industry:
Inflammation and Allergy
Website:
Company status:
Private
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat allergy and inflammation, is developing UPB-101, a clinical-stage monoclonal antibody that inhibits the TSLP receptor.
